CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise
On August 13, 2026, Cadrenal Therapeutics, Inc. (CVKD) announced financial results for the second quarter of 2026 and provided a business...
98 Views
CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy
Following the recent positive CAD-1005 Phase 2 presentation at ISTH 2026, Cadrenal Therapeutics, Inc. (CVKD) announced the initiation of a formal...
110 Views
CVKD: Designing Phase 3 Trial for CAD-1005 in HIT
On May 7, 2026, Cadrenal Therapeutics, Inc. (CVKD) announced financial results for the first quarter of 2026 and provided a business update. The...
91 Views
CVKD: Results Show 12-LOX Inhibition Targets Inflammation from Obesity and Type 2 Diabetes
On March 12, 2026, Cadrenal Therapeutics, Inc. (CVKD) announced recent findings that support the use of its first-in-class 12-lipoxygenase...
104 Views
CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events
On February 24, 2026, Cadrenal Therapeutics, Inc. (CVKD) announced encouraging results from the company's Phase 2 trial evaluating CAD-1005...
130 Views